Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MPS PharmaaBOM:531686 11 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates BOM:531686 with a GF Score™ of 11/100. The stock has 3 warning signs investors should review. Among 960 Drug Manufacturers companies, MPS Pharmaa ranks worse than 104166.56% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. MPS Pharmaa's Free Cash Flow for the
three
months ended in Mar. 2026 was ₹0.00 Mil. MPS Pharmaa's Revenue for the
three
months ended in Mar. 2026 was ₹0.00 Mil. Therefore, MPS Pharmaa's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.
The historical rank and industry rank for MPS Pharmaa's FCF Margin % or its related term are showing as below:
During the past 13 years, the highest FCF Margin % of MPS Pharmaa was 45.94%. The lowest was -13431.17%. And the median was 3.95%.
BOM:531686's FCF Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.39 * Ranked among companies with meaningful FCF Margin % only.
The historical data trend for MPS Pharmaa's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, MPS Pharmaa's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MPS Pharmaa FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MPS Pharmaa's FCF Margin % distribution charts can be found below:
* The bar in red indicates where MPS Pharmaa's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MPS Pharmaa (BOM:531686) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on MPS Pharmaa and its competitors. According to the industry distribution chart, MPS Pharmaa ranks #999999 out of 960 companies in the Drug Manufacturers industry.
Is MPS Pharmaa's FCF Margin % too high?
MPS Pharmaa's current FCF Margin % is 0.00%. Based on the distribution chart, MPS Pharmaa ranks #999999 out of 960 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, MPS Pharmaa has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does MPS Pharmaa's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, MPS Pharmaa ranks #999999 out of 960 companies for FCF Margin %. This places MPS Pharmaa in the lower half of its industry. The industry median FCF Margin % is 2.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.39, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on MPS Pharmaa and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MPS Pharmaa's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MPS Pharmaa stock overvalued right now?
MPS Pharmaa (BOM:531686) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. MPS Pharmaa's overall GF Score™ is 11/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For MPS Pharmaa (BOM:531686), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MPS Pharmaa Ltd is an India-based pharmaceutical company. It is principally engaged in manufacturing, marketing, trading, and exporting Pharmaceutical Products. The company manufactures and exports medicines that include antihypertensive medicines, antihypertensive tablets, antifungal tablets, antifungal capsules, erectile dysfunction drugs, sedatives, corticosteroid medicines, antimalarials, anthelmintics, antipyretic & anti-inflammatory, and antibacterials & antibiotics. Its products include Wibatol, Robial, Twosum, Arfa Gel, and others.
11GF Score
Get the complete analysis for BOM:531686
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531686 has been successfully added to your 
